[go: up one dir, main page]

MXPA02012890A - Uso de compuestos de indol sustituidos para incrementar la actividad de oxido nitrico sintasa. - Google Patents

Uso de compuestos de indol sustituidos para incrementar la actividad de oxido nitrico sintasa.

Info

Publication number
MXPA02012890A
MXPA02012890A MXPA02012890A MXPA02012890A MXPA02012890A MX PA02012890 A MXPA02012890 A MX PA02012890A MX PA02012890 A MXPA02012890 A MX PA02012890A MX PA02012890 A MXPA02012890 A MX PA02012890A MX PA02012890 A MXPA02012890 A MX PA02012890A
Authority
MX
Mexico
Prior art keywords
methods
nitric oxide
oxide synthase
synthase activity
increasing nitric
Prior art date
Application number
MXPA02012890A
Other languages
English (en)
Inventor
Steven Jay Adelman
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MXPA02012890A publication Critical patent/MXPA02012890A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
MXPA02012890A 2000-07-06 2001-06-29 Uso de compuestos de indol sustituidos para incrementar la actividad de oxido nitrico sintasa. MXPA02012890A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21618700P 2000-07-06 2000-07-06
PCT/US2001/021083 WO2002003991A2 (en) 2000-07-06 2001-06-29 Use of substituted indole compounds for increasing nitric oxide synthase activity

Publications (1)

Publication Number Publication Date
MXPA02012890A true MXPA02012890A (es) 2003-10-24

Family

ID=22806070

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02012890A MXPA02012890A (es) 2000-07-06 2001-06-29 Uso de compuestos de indol sustituidos para incrementar la actividad de oxido nitrico sintasa.

Country Status (9)

Country Link
US (1) US20020022617A1 (es)
EP (1) EP1296674A2 (es)
JP (1) JP2004502734A (es)
CN (1) CN1635885A (es)
AU (1) AU7178301A (es)
BR (1) BR0112360A (es)
CA (1) CA2414111A1 (es)
MX (1) MXPA02012890A (es)
WO (1) WO2002003991A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1531807A4 (en) * 2002-06-13 2007-10-31 Wyeth Corp Bazedoxifene TREATMENT SCHEMES
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
MX2007011453A (es) * 2005-04-22 2008-02-12 Alantos Pharmaceuticals Holding Inc Inhibidores de la dipeptidil peptidasa-iv.
JP5350219B2 (ja) * 2006-04-13 2013-11-27 ニューラクソン，インコーポレーテッド Ｎｏｓ阻害活性を有する１，５および３，６−置換インドール化合物
JP5558104B2 (ja) * 2006-12-11 2014-07-23 スリー−ディー マトリックス， インコーポレイテッド 心組織の保護および再生のための組成物および方法
CN113248494A (zh) 2015-10-01 2021-08-13 奥列马制药公司 四氢-1H-吡啶[3,4-b]吲哚类抗雌激素药物
US20170166551A1 (en) 2015-12-09 2017-06-15 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulator compounds
ES2989988T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros heterorocíclicos para la degradación de proteínas diana
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
BR112018077136A2 (pt) 2016-07-01 2019-04-30 G1 Therapeutics, Inc. composto, e, métodos para tratar um distúrbio associado com proliferação celular anormal e para reduzir o efeito de quimioterapia em células saudáveis.
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
MX2019008158A (es) 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
KR20190117582A (ko) 2017-02-10 2019-10-16 쥐원 쎄라퓨틱스, 인크. 벤조티오펜 에스트로겐 수용체 조정제
WO2018237026A1 (en) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
CA3067873A1 (en) 2017-06-29 2019-01-03 G1 Therapeutics, Inc. Morphic forms of g1t38 and methods of manufacture thereof
CN107951034B (zh) * 2017-12-01 2021-03-23 郑州拓洋生物工程有限公司 维生素泡腾制剂及其制备方法
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN BREAKDOWN
AU2020311337A1 (en) 2019-07-07 2022-01-20 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists
WO2021127561A1 (en) 2019-12-20 2021-06-24 C4 Therapeutics, Inc. Isoindolinone and indazole compounds for the degradation of egfr
KR20220166797A (ko) 2020-03-05 2022-12-19 씨4 테라퓨틱스, 인코포레이티드 Brd9의 표적화된 분해를 위한 화합물
JP2023538517A (ja) 2020-08-05 2023-09-08 シーフォー セラピューティクス， インコーポレイテッド Ｒｅｔの標的分解のための化合物
TW202313628A (zh) 2021-06-08 2023-04-01 美商Ｃ４醫藥公司 用於降解突變braf之治療劑
KR20250055538A (ko) 2022-08-03 2025-04-24 브리스톨-마이어스 스큅 컴퍼니 Ret 단백질을 조정하기 위한 화합물
EP4611900A1 (en) 2022-11-04 2025-09-10 Bristol-Myers Squibb Company Ret-ldd protein inhibitors
CN120569388A (zh) 2022-11-04 2025-08-29 百时美施贵宝公司 Ret-ldd蛋白降解剂
WO2025006753A2 (en) 2023-06-30 2025-01-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ314601A (en) * 1996-04-19 1999-09-29 American Home Prod 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole derivatives as estrogenic agents and pharmaceutical compositions
TW397821B (en) * 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5880137A (en) * 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
JP2001523254A (ja) * 1997-04-30 2001-11-20 イーライ・リリー・アンド・カンパニー 抗血栓剤
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
AU7896100A (en) * 1999-10-14 2001-04-23 Endorecherche Inc. Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
CO5271696A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Procedimiento para reducir la morbilidad y el riesgo de mortalidad
CO5251465A1 (es) * 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
IL149990A0 (en) * 2000-01-28 2002-12-01 Endorech Inc Selective estrogen receptor modulators in combination with estrogens

Also Published As

Publication number Publication date
JP2004502734A (ja) 2004-01-29
CN1635885A (zh) 2005-07-06
WO2002003991A3 (en) 2002-07-04
AU7178301A (en) 2002-01-21
EP1296674A2 (en) 2003-04-02
CA2414111A1 (en) 2002-01-17
US20020022617A1 (en) 2002-02-21
BR0112360A (pt) 2003-05-06
WO2002003991A2 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
MXPA02012890A (es) Uso de compuestos de indol sustituidos para incrementar la actividad de oxido nitrico sintasa.
GB0031179D0 (en) Nitric oxide synthase inhibitors
ZA98179B (en) Nitric oxide synthase inhibitors.
MX243820B (es) Oxido de metal particulado.
AP2000001998A0 (en) Nitric oxide synthase inhibitors
MXPA03002410A (es) 4-amino-quinazolinas.
EP1429829A4 (en) NITROGEN OXIDE GENERATION
MXPA01011516A (es) Incinerador de pared radiante de bajo nox.
ZA200007669B (en) Insert.
EG23262A (en) Delta -pyrrolines.
EP1272455A4 (en) HALOGENIC DERIVATIVES OF 2-AMINO-4,5 HEPTENOIC ACID, USEFUL AS INHIBITOR OF NITRIC OXIDE SYNTHASE
MXPA01010764A (es) Ensamble de quemador de emisiones bajas en nox y metodo para reducir el contenido de nox de gas de combustion de alto horno.
MXPA03001591A (es) Derivados y analogos de 10-aril-11-h-benzo(b) fluorena para uso medicinal.
MXPA03001877A (es) 2-guanidin-4-arilquinazolinas.
ZA200205389B (en) Booklet.
MXPA03002668A (es) Guanidinas de sulfonilo.
MXPA03003376A (es) Celda.
EP1282420A4 (en) HALOGENED 2-AMINO-3,4-HEPTENIC ACID DERIVATE NITROGEN MONOXIDE SYNTHASE INHIBITORS
MXPA03005714A (es) Sulfamidotienopirimidinas.
AU2001282746A1 (en) Novel phenylheteroazetidines, useful as nitric oxide synthase inhibitors
MXPA01006792A (es) Bateria.
AU2001234538A1 (en) Nitric oxide synthase gene diagnostic polymorphisms
AU2002350575A1 (en) Selective neuronal nitric oxide synthase inhibitors
MXPA03002521A (es) Triazol-epotilona.
MXPA03004019A (es) Metodo de pasivacion.